Ex-vivo screening platform to identify tumor-specific therapies

We report the generation of a preclinical IBC patient-derived xenograft (PDX)-derived ex vivo tumor tissue model and show that it closely replicates the tissue architecture of the original PDX tumor harvested from mice and show that its genetic signature highly correlates with that of the original tumor. We used microarrays to evaluate the robustness and reproducibility of the method used to generate the ex vivo tumor tissue model and confirm its ability to recapitulate the essential features of the original tumor. We chronicle the development of an IBC PDX-derived ex vivo tumor tissue model generated from the cellular milieu released from a PDX tumor harvested from a mouse and demonstrated its predictive value in identifying tumor-specific therapies in a time and cost effective manner.